By Fineline Cube 
UK-based AstraZeneca’s (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a significant structural reorganization. The company announced the formation of two new business units: the Respiratory Biologics and Autoimmune Business Unit and the Respiratory Inhalation Business Unit.
Respiratory Biologics and Autoimmune Business Unit
The Respiratory Biologics and Autoimmune Business Unit will focus on biologics and future autoimmune product pipelines. It will cover key product lines including Fasenra, Tezspire, Tozorakimab, and Saphnelo. This unit requires strong academic capabilities to drive the transition towards biologics. Sophie Zhang will join AstraZeneca China on July 29 as Assistant Vice President and Head of this new unit. She will also be part of the AstraZeneca China Management Team, reporting directly to Leon Lin, General Manager of AstraZeneca China.
Respiratory Inhalation Business Unit
The Respiratory Inhalation Business Unit will continue to collaborate closely with omnichannel teams to align with national grassroots healthcare policies. It aims to expand into lower-tier markets and extend innovative therapies from core hospitals to communities. This unit will include the Breztri, Symbicort, and Bevespi product lines. William Tong, currently Assistant Vice President and Head of the COPD Business at AstraZeneca China, will lead this new unit as Assistant Vice President and Head of the Respiratory Inhalation Business Unit, reporting directly to Leon Lin.
Leadership Promotions
Additionally, AstraZeneca has promoted Baiyang Li, the current Head of Retail Business, to Assistant Vice President and Head of Retail Business for AstraZeneca China.-Fineline Info & Tech